公开(公告)号：US20070043035A1

公开(公告)日：2007-02-22

申请号：US10575122

申请日：2004-01-29

申请人： Ranga Gurram ,  Debnath Bhuniya ,  Saibal Das ,  Sudhir Sharma ,  Ranjan Chakrabarti ,  Javed Iqbal

发明人： Ranga Gurram ,  Debnath Bhuniya ,  Saibal Das ,  Sudhir Sharma ,  Ranjan Chakrabarti ,  Javed Iqbal

IPC分类号： A61K31/5415 ,  A61K31/5377 ,  A61K31/47 ,  A61K31/405 ,  A61K31/4035

CPC分类号： C07C69/757 ,  C07B2200/07 ,  C07C33/28 ,  C07C59/68 ,  C07C67/30 ,  C07C67/31 ,  C07C69/712 ,  C07C217/84 ,  C07C309/66 ,  C07C323/52 ,  C07C2601/08 ,  C07C2603/18 ,  C07D233/64 ,  C07D265/38 ,  C07D279/22

摘要： The present invention relates to novel hypolipidemic, antiobesity, hypocholesterolemic and antidiabetic compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their stereoisomers, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them where all symbols are as defined in the description.

摘要翻译： 本发明涉及新型降血脂，抗肥胖，低胆固醇血症和抗糖尿病化合物。 更具体地，本发明涉及通式（I）的新型烷基羧酸，其立体异构体，其药学上可接受的盐和含有它们的药物组合物，其中所有符号如说明书中所定义。

公开(公告)号：US20060089500A1

公开(公告)日：2006-04-27

申请号：US11296749

申请日：2005-12-07

申请人： Ranga Gurram ,  Venkateswarlu Akella ,  Rajagopalan Ramanujam ,  Ranjan Chakrabarti ,  Parimal Misra ,  Vidya Lohray ,  Braj Lohray ,  Rao Paraselli

发明人： Ranga Gurram ,  Venkateswarlu Akella ,  Rajagopalan Ramanujam ,  Ranjan Chakrabarti ,  Parimal Misra ,  Vidya Lohray ,  Braj Lohray ,  Rao Paraselli

IPC分类号： A61K31/513 ,  C07D239/02

CPC分类号： C07D239/36 ,  C07C217/22 ,  C07C237/32 ,  C07C247/04 ,  C07D239/90

摘要： The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel β-aryl-α-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to novel intermediates, processes for their preparation and their use in the preparation of compounds of formula (I).

公开(公告)号：US20050032864A1

公开(公告)日：2005-02-10

申请号：US10917221

申请日：2004-08-12

申请人： Vidya Lohray ,  Braj Lohray ,  Rao Paraselli ,  Ranga Gurram ,  Rajagopalan Ramanujam ,  Ranjan Chakrabarti ,  Sarma Pakala

发明人： Vidya Lohray ,  Braj Lohray ,  Rao Paraselli ,  Ranga Gurram ,  Rajagopalan Ramanujam ,  Ranjan Chakrabarti ,  Sarma Pakala

IPC分类号： C07D239/36 ,  C07D239/46 ,  C07D239/88 ,  C07D241/34 ,  C07D277/34 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04 ,  A61K31/4178 ,  C07D43/02

CPC分类号： C07D239/36 ,  C07D239/47 ,  C07D239/88 ,  C07D277/34 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D495/04

摘要： The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.

摘要翻译： 本发明涉及新的抗糖尿病化合物，其互变异构形式，其衍生物，其立体异构体，其多晶型物，其药学上可接受的盐，其药学上可接受的溶剂合物和含有它们的药学上可接受的组合物。 本发明特别涉及通式（I）的新的唑来二酮衍生物及其药学上可接受的盐，药学上可接受的溶剂合物和含有它们的药物组合物。

公开(公告)号：US20070093476A1

公开(公告)日：2007-04-26

申请号：US10577698

申请日：2004-10-20

申请人： Bhunia Debnath ,  Ranga Gurram ,  Das Saibal Kumar ,  Iqbal Javed ,  Chakrabarti Ranjan ,  Kole Labanyamoy

发明人： Bhunia Debnath ,  Ranga Gurram ,  Das Saibal Kumar ,  Iqbal Javed ,  Chakrabarti Ranjan ,  Kole Labanyamoy

IPC分类号： A61K31/5415 ,  A61K31/538 ,  A61K31/4704 ,  A61K31/404 ,  A61K31/195

CPC分类号： C07C311/08 ,  C07C37/002 ,  C07C39/17 ,  C07C45/30 ,  C07C69/712 ,  C07C69/757 ,  C07C205/22 ,  C07C205/37 ,  C07C205/56 ,  C07C217/86 ,  C07C271/28 ,  C07C309/66 ,  C07C309/73 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/10 ,  C07D209/08 ,  C07D215/06 ,  C07D265/36 ,  C07C47/575 ,  C07C39/11

摘要： The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH2)p′(CH2)pB(CH2)q′(CH2)rB(CH2)pD(CH2)p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R4 represents hydrogen, alkyl, alkenyl, —S(O)2—R8 or —C(O)R8 where R8 is alkyl, alkoxy; R5 and R6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R5 and R6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.